Progenics pharmaceuticals inc (PGNX)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Cash flows from operating activities:
Net loss

-16,801

-11,275

-18,842

-19,700

-18,735

-14,704

-24,357

-15,172

-13,424

-2,665

-15,352

-16,636

-16,360

-7,219

36,282

-5,657

-12,673

-7,154

-10,014

-11,697

-10,254

-12,179

36,975

-11,073

-9,313

-8,551

-10,500

-12,263

-11,258

-324

-11,301

-10,720

-13,086

-10,746

-11,432

55,486

-22,927

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

878

1,105

1,216

994

1,077

908

1,123

2,130

1,048

1,018

935

1,586

603

499

422

960

576

243

494

1,454

757

648

624

1,478

773

643

804

1,350

749

786

954

2,187

2,609

1,667

1,422

1,778

1,495

Depreciation and amortization

742

599

601

609

557

483

424

304

286

289

288

288

256

218

362

747

751

167

137

129

132

126

142

133

144

165

179

318

277

261

291

300

472

485

520

525

536

Gain on sale of fixed assets

-

-

-

-

-

-

-

-

-

-

-

-25

15

-

8

171

112

1

19

-16

-2

235

-52

-30

-43

-418

-45

334

-75

634

-90

-310

93

0

0

0

0

Paid in-kind interest

-

-

-

-

-

-

-

-

-

-

-

0

-13

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense

61

65

67

68

71

73

92

74

63

75

50

61

61

38

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other

-

0

0

0

-11

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of contingent consideration liability

-300

-400

-500

916

900

100

-8,000

1,300

800

-700

700

700

1,900

-6,000

600

600

200

700

-200

800

300

100

500

400

500

-200

0

0

0

-

-

-

-

-

-

-

-

Changes in assets and liabilities:
Accounts receivable

-9,786

9,802

-4,390

5,628

1,136

-2,017

1,977

327

-491

1,353

-97

619

-2,767

919

383

1,224

-1,204

2,005

2,710

-1,257

-43

36,018

-40,199

-651

2,062

-10,354

496

342

5,402

5,034

967

-1,467

887

-996

-2,947

1,617

1,559

Other current assets

-968

548

277

1,626

447

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other current assets

-

-

-

-

-

-

-

-

204

-

-1,618

-388

-638

561

-1,561

134

-448

-439

3,614

374

-491

2,831

-2,259

905

-905

-1,377

229

372

440

998

-138

-98

-8

104

-1,642

1,123

-467

Other assets

-

-

-

-

-

-

-

-

-

-

-

0

0

-558

1,027

0

0

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

0

0

-2,100

1,050

Other assets

-286

-347

-323

2,851

-146

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

1,618

568

409

-293

124

-192

83

-1,040

-1,757

2,252

-30

155

402

-527

37

-423

1,156

-1,998

1,686

70

40

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Decrease) increase in deferred revenue - long term

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

60,000

Accrued expenses

-4,888

618

-4,452

7,437

-991

2,883

-1,797

1,555

-1,632

-542

-4,014

1,348

-3,066

3,083

653

2,332

513

893

1,625

1,145

-1,309

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

93

(Increase) in other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1

-

-

-

-

-

-

-

-

-

-

-

-

Increase (decrease) in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,802

256

-2,531

609

-57

-1,878

-630

-846

2,503

-116

-2,232

-550

838

-1,792

-1,848

Other current liabilities

217

20

21

21

18

-

-

-

-

-

-

0

0

1

-285

185

-59

-60

0

0

0

-

-

-

-

-1,236

-53

-320

-460

2,069

0

0

0

-

-

-

-

(Decrease) in deferred revenue - long term

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-9

-51

-51

-51

-51

-51

262

2

Other liabilities

-174

-130

-127

-128

-114

73

73

72

73

81

80

81

81

519

548

-753

29

-43

-12

-13

-12

-1

0

-1

-1

-1

0

-167

4

39

40

36

-534

-

-

-

-

Net cash used in operating activities

-7,607

-18,827

-17,171

-20,181

-18,519

-8,910

-12,653

-10,933

-14,256

-13,123

-15,615

-12,623

-12,746

-7,739

38,762

-3,538

-7,967

-10,486

-9,758

-9,011

-10,882

31,616

90

-8,665

-9,315

-9,697

-8,947

-11,912

-5,551

-5,730

-6,825

-8,295

-13,794

-8,401

-5,372

-7,333

39,493

Cash flows from investing activities:
Acquisition of AZEDRA manufacturing assets

-

0

0

0

8,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash acquired in acquisition of subsidiary

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1,888

0

0

0

0

-

-

-

-

Purchases of property and equipment

3,553

2,766

2,638

1,336

491

222

93

486

16

6

23

95

145

1,025

526

2,128

607

96

41

180

53

387

259

58

10

60

30

12

35

8

28

213

518

84

50

63

29

Proceeds from sale of fixed assets

-

-

-

-

-

-

-

-

-

0

0

5

32

6

27

201

113

2

29

15

2

15

52

30

46

21

49

18

86

22

105

139

124

-

-

-

-

Net cash used in investing activities

-3,553

-2,766

-2,638

-1,613

-8,491

-222

-93

-486

-16

-6

-23

-90

-113

-1,019

-499

-1,927

-494

-6,296

-12

-165

-51

2,028

-207

-28

36

-39

19

1,006

2,039

14

77

-74

-294

16

50

37

-29

Cash flows from financing activities:
Net proceeds common stock

-

-

-

-

-

-

-

15,291

9,524

-

-

0

0

-

-

-

-

-

-

-

-

0

0

4

37,455

-1

5,236

34,843

0

-

-

-

-

-

-

-

-

Repayment of debt

1,682

1,963

1,290

1,553

1,037

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Equity issuance costs in connection with acquisition of subsidiary

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-45

0

0

0

0

-

-

-

-

Proceeds from exercise of stock options

162

-

-

-

-

-

-

-

-

-1

59

179

232

830

499

11

0

722

899

55

61

428

0

0

0

0

68

0

3

110

24

90

82

492

915

1,047

1,272

Proceeds from sales of fixed assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from redemption of auction rate securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1,000

100

0

0

0

100

100

100

100

0

Net cash used in financing activities

-1,520

-1,334

-244

-1,286

-1,037

-2,022

74,103

13,112

9,524

5,019

-73

332

232

49,112

499

11

0

430

899

55

61

428

0

4

37,455

-1

5,304

34,843

-42

23,458

24

90

82

492

915

1,047

1,272

Effect of currency rate changes on cash, cash equivalents and restricted cash

-201

172

-222

48

-46

-6

7

-76

-17

-10

33

35

25

-30

-14

-75

33

17

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net decrease in cash, cash equivalents, and restricted cash

-12,881

-22,755

-20,275

-23,032

-28,093

-11,160

61,364

1,617

-4,765

-8,120

-15,678

-12,346

-12,602

40,324

38,748

-5,529

-8,428

-16,335

-8,871

-9,121

-10,872

34,072

-117

-8,689

28,176

-9,737

-3,624

23,937

-3,554

17,742

-6,724

-8,279

-14,006

-7,893

-4,407

-6,249

40,736

Supplemental disclosure of cash flow information
Cash paid for interest

939

985

1,015

1,054

1,077

1,125

1,154

1,176

1,205

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Noncash financing activity
Subscription receivable

-

-

-

-

-

-

-

-

-1,359

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-